Alexander Guminski

13.3k total citations · 2 hit papers
114 papers, 4.2k citations indexed

About

Alexander Guminski is a scholar working on Oncology, Molecular Biology and Epidemiology. According to data from OpenAlex, Alexander Guminski has authored 114 papers receiving a total of 4.2k indexed citations (citations by other indexed papers that have themselves been cited), including 79 papers in Oncology, 43 papers in Molecular Biology and 32 papers in Epidemiology. Recurrent topics in Alexander Guminski's work include Cancer Immunotherapy and Biomarkers (45 papers), CAR-T cell therapy research (35 papers) and Nonmelanoma Skin Cancer Studies (29 papers). Alexander Guminski is often cited by papers focused on Cancer Immunotherapy and Biomarkers (45 papers), CAR-T cell therapy research (35 papers) and Nonmelanoma Skin Cancer Studies (29 papers). Alexander Guminski collaborates with scholars based in Australia, United States and Germany. Alexander Guminski's co-authors include Georgina V. Long, Alexander M. Menzies, Serigne Lo, Richard A. Scolyer, Matteo S. Carlino, Victoria Atkinson, Shahneen Sandhu, Richard Kefford, Grant A. McArthur and Michael P. Brown and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and The Journal of Clinical Endocrinology & Metabolism.

In The Last Decade

Alexander Guminski

105 papers receiving 4.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study

2018 655 citations Georgina V. Long, Victoria Atkinson et al. The Lancet Oncology profile →
Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab

2016 604 citations Alexander M. Menzies, Victoria Atkinson et al. Annals of Oncology profile →

Peers

Countries citing papers authored by Alexander Guminski

Since Specialization

Citations

This map shows the geographic impact of Alexander Guminski's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Alexander Guminski with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Alexander Guminski more than expected).

Fields of papers citing papers by Alexander Guminski

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Alexander Guminski. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Alexander Guminski. The network helps show where Alexander Guminski may publish in the future.

Co-authorship network of co-authors of Alexander Guminski

This figure shows the co-authorship network connecting the top 25 collaborators of Alexander Guminski. A scholar is included among the top collaborators of Alexander Guminski based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Alexander Guminski. Alexander Guminski is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Development of a First-in-Class Click Chemistry–Based Cancer Therapeutic, from Preclinical Evaluation to a First-in-Human Dose Escalation Clinical Trial 2025 ·Clinical Cancer Research ·Sangeetha Srinivasan, Nathan K. Yee, Maša Alečković, (unknown), (unknown), (unknown), Tri‐Hung Nguyen, Sant P. Chawla, Alexander Guminski, (unknown)	0
2	Oral Microbiome as a Biomarker and Therapeutic Target in Head and Neck Cancer: Current Insights and Future Directions 2025 ·Cancers ·(unknown), Dasantha Jayamanne, (unknown), (unknown), Alexander Guminski, Adrian V. Lee, (unknown), Helen Wheeler, Thomas Eade, Michael Back, Mark P. Molloy, Byeongsang Oh	0
3	Ipilimumab plus nivolumab versus nivolumab alone in patients with melanoma brain metastases (ABC): 7-year follow-up of a multicentre, open-label, randomised, phase 2 study 2025 ·The Lancet Oncology ·Georgina V. Long, Victoria Atkinson, Serigne Lo, Alexander Guminski, Shahneen Sandhu, Michael P. Brown, Maria Gonzalez, Grant A. McArthur, Alexander M Menzies	9
4	Immune checkpoint inhibitor therapy for advanced cutaneous squamous cell carcinoma in Australia: a retrospective real world cohort study 2024 ·The Medical Journal of Australia ·(unknown), Annette M. Lim, Mathias Bressel, Jenny Lee, Rahul Ladwa, Alexander Guminski, Brett Hughes, Samantha Bowyer, Karen Briscoe, S.J. Harris, (unknown), Robert Zielinski, Muhammad Alamgeer, Matteo S. Carlino, (unknown), John Park, Muhammad A. Khattak, Fiona Day, Danny Rischin	8
5	Position statement on classification of basal cell carcinomas. Part 1: unsupervised clustering of experts as a way to build an operational classification of advanced basal cell carcinoma based on pattern recognition 2021 ·Journal of the European Academy of Dermatology and Venereology ·Jean‐Jacques Grob, Alexander Guminski, Josep Malvehy, Nicole Basset‐Séguin, Baptiste Bertrand, Pablo Fernández‐Peñas, Roland Kaufmann, Iris Zalaudek, Caroline Gaudy‐Marqueste, Maria Concetta Fargnoli, Luca Tagliaferri, Bernard Fertil, V. del Mármol, Alexander Stratigos, Claus Garbe, Ketty Peris	12
6	LBA36 Nivolumab (N) + ipilimumab (I) vs EXTREME as first-line (1L) treatment (tx) for recurrent/metastatic squamous cell carcinoma of the head and neck (R/M SCCHN): Final results of CheckMate 651 2021 ·Annals of Oncology ·Athanassios Argiris, Kevin J. Harrington, Makoto Tahara, Robert L. Ferris, Maura L. Gillison, Jérôme Fayette, Amaury Daste, P. Koralewski, (unknown), Nabil F. Saba, Milena Perez Mak, Miguel Ángel Álvarez-Avitia, Alexander Guminski, Urs Müller‐Richter, Naomi Kiyota, Mustimbo Roberts, (unknown), (unknown), Wei Li, (unknown)	21
7	Why pathologists and oncologists should know about tumour-infiltrating lymphocytes (TILs) in triple-negative breast cancer: an Australian experience of 139 cases 2020 ·Pathology ·Talia L. Fuchs, A. Scott Pearson, (unknown), Connie I. Diakos, (unknown), David Chan, Alexander Guminski, Alexander M. Menzies, Sally Baron‐Hay, Amy Sheen, Loretta Sioson, Angela Chou, Anthony J. Gill	3
8	Long-term Follow-up of Standard-Dose Pembrolizumab Plus Reduced-Dose Ipilimumab in Patients with Advanced Melanoma: KEYNOTE-029 Part 1B 2020 ·Clinical Cancer Research ·Matteo S. Carlino, Alexander M. Menzies, Victoria Atkinson, Jonathan Cebon, Michael B. Jameson, Bernard M. Fitzharris, Catriona M. McNeil, Andrew Hill, Antoni Ribas, Michael B. Atkins, John A. Thompson, Wen‐Jen Hwu, F. Stephen Hodi, Alexander Guminski, Richard Kefford, Haiyan Wu, Nageatte Ibrahim, Blanca Homet Moreno, Georgina V. Long	30
9	Circulating Cytokines Predict Immune-Related Toxicity in Melanoma Patients Receiving Anti-PD-1–Based Immunotherapy 2018 ·Clinical Cancer Research ·Su Yin Lim, Jenny Lee, Tuba N. Gide, Alexander M. Menzies, Alexander Guminski, Matteo S. Carlino, Edmond J. Breen, Jean Yang, Shila Ghazanfar, Richard Kefford, Richard A. Scolyer, Georgina V. Long, Helen Rizos	271
10	OpACIN-neo: A multicenter phase II study to identify the optimal neo-adjuvant combination scheme of ipilimumab (IPI) and nivolumab (NIVO) 2018 ·Annals of Oncology ·Christian U. Blank, Elisa A. Rozeman, Alexander M. Menzies, Bart A. van de Wiel, Chandra Mani Adhikari, Karolina Sikorska, Oscar Krijgsman, Hanna Eriksson, Carolien Bierman, Lindsay G. Grijpink-Ongering, Maria Gonzalez, Annegien Broeks, Alexander Guminski, Andrew J. Spillane, W. Martin C. Klop, Robyn P.M. Saw, Richard A. Scolyer, Alexander C. J. van Akkooi, Johan Hansson, Georgina V. Long	12
11	Dynamic Changes in PD-L1 Expression and Immune Infiltrates Early During Treatment Predict Response to PD-1 Blockade in Melanoma 2017 ·Clinical Cancer Research ·Ricardo E. Vilain, Alexander M. Menzies, James S. Wilmott, Hojabr Kakavand, Jason Madore, Alexander Guminski, Elizabeth Liniker, Benjamin Y. Kong, Adam Cooper, Julie R. Howle, Robyn P.M. Saw, Valerie Jakrot, Serigne Lo, John F. Thompson, Matteo S. Carlino, Richard Kefford, Georgina V. Long, Richard A. Scolyer	191
12	Real‐world experience of the feasibility and tolerability of the 2/1 dosing schedule with sunitinib in the treatment of patients with advanced renal cell carcinoma in Australia 2017 ·Asia-Pacific Journal of Clinical Oncology ·Megan Crumbaker, Alexander Guminski, Howard Gurney, Dhanusha Sabanathan, Shirley Wong, Nick Pavlakis	5
13	Long‐term efficacy and safety of sonidegib in patients with locally advanced and metastatic basal cell carcinoma: 30‐month analysis of the randomized phase 2 BOLT study 2017 ·Journal of the European Academy of Dermatology and Venereology ·John T. Lear, Michael R. Migden, Karl D. Lewis, Anne Lynn S. Chang, Alexander Guminski, Ralf Gutzmer, Luc Dirix, P. Combemale, Alexander Stratigos, Ruth Plummer, Henry Castro, Tingting Yi, Manisha Mone, (unknown), Uwe Trefzer, Martin Kaatz, Carmen Loquai, Ragini R. Kudchadkar, Dalila Sellami, Reinhard Dummer	137
14	A Phase II, Randomised, Open Label Study of Neoadjuvant Pembrolizumab with/without Dabrafenib and Trametinib (D+T) in BRAF V600 Mutant Resectable Stage IIIB/C/D Melanoma (NeoTrio Trial) 2017 ·Annals of Oncology ·Maria Gonzalez, Alexander M. Menzies, Robyn P.M. Saw, John F. Thompson, Andrew J. Spillane, Julie R. Howle, Omgo E. Nieweg, Kerwin F. Shannon, Sydney Ch’ng, Jonathan R. Stretch, Matteo S. Carlino, Alexander Guminski, Louise Emmett, Helen Rizos, Richard A. Scolyer, Georgina V. Long	7
15	Safety and efficacy of anti-PD-1 antibodies in elderly patients with metastatic melanoma 2016 ·Annals of Oncology ·Robba Rai, Jennifer L. McQuade, (unknown), (unknown), (unknown), Jeffrey A. Sosman, Kathryn E. Beckermann, Lauren E. Haydu, Serigne Lo, Samuel M. Rubinstein, Meredith McKean, Susan Matthew, Alexander Guminski, Matteo S. Carlino, Michael A. Davies, (unknown), Georgina V. Long, Alexander M. Menzies	14
16	New systemic treatment options for advanced basal cell carcinoma 2012 ·Cancer Forum ·Alexander Guminski	0
17	Loss of Osteoclasts Contributes to Development of Osteosarcoma Pulmonary Metastases 2010 ·Cancer Research ·Liliana Endo‐Munoz, A. Cumming, Danny Rickwood, (unknown), (unknown), Charlotte K.Y. Ng, Geoffrey Strutton, A. Ian Cassady, Andreas Evdokiou, Scott Sommerville, Ian C. Dickinson, Alexander Guminski, Nicholas A. Saunders	63
18	Cisplatin Treatment Induces a Transient Increase in Tumorigenic Potential Associated with High Interleukin-6 Expression in Head and Neck Squamous Cell Carcinoma 2010 ·Molecular Cancer Therapeutics ·(unknown), Alexander Guminski, Gethin Thomas, Paul Leo, (unknown), Nicholas A. Saunders	43
19	Tumor-initiating activity and tumor morphology of HNSCC is modulated by interactions between clonal variants within the tumor 2010 ·Laboratory Investigation ·Sarina Cameron, Alison Dahler, Liliana Endo‐Munoz, (unknown), Gethin Thomas, Paul Leo, (unknown), Danny Rickwood, Alexander Guminski, Nicholas A. Saunders	24
20	Scientists and clinicians test their metal–back to the future with platinum compounds 2002 ·The Lancet Oncology ·Alexander Guminski, Paul R. Harnett, Anna DeFazio	21

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact